JP2018529656A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018529656A5 JP2018529656A5 JP2018509504A JP2018509504A JP2018529656A5 JP 2018529656 A5 JP2018529656 A5 JP 2018529656A5 JP 2018509504 A JP2018509504 A JP 2018509504A JP 2018509504 A JP2018509504 A JP 2018509504A JP 2018529656 A5 JP2018529656 A5 JP 2018529656A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- dll3
- cancer cells
- ihc assay
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562207830P | 2015-08-20 | 2015-08-20 | |
| US62/207,830 | 2015-08-20 | ||
| US201662323998P | 2016-04-18 | 2016-04-18 | |
| US62/323,998 | 2016-04-18 | ||
| US201662373906P | 2016-08-11 | 2016-08-11 | |
| US62/373,906 | 2016-08-11 | ||
| PCT/US2016/047870 WO2017031458A2 (en) | 2015-08-20 | 2016-08-19 | Anti-dll3 antibody drug conjugates and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018529656A JP2018529656A (ja) | 2018-10-11 |
| JP2018529656A5 true JP2018529656A5 (enExample) | 2019-09-26 |
Family
ID=58052015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018509504A Ceased JP2018529656A (ja) | 2015-08-20 | 2016-08-19 | 抗ｄｌｌ３抗体薬物コンジュゲートおよび使用方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20180243435A1 (enExample) |
| EP (1) | EP3337517A4 (enExample) |
| JP (1) | JP2018529656A (enExample) |
| KR (1) | KR20180041717A (enExample) |
| CN (1) | CN108136015A (enExample) |
| AU (1) | AU2016308365A1 (enExample) |
| BR (1) | BR112018003269A2 (enExample) |
| CA (1) | CA2996165A1 (enExample) |
| CL (2) | CL2018000458A1 (enExample) |
| CO (1) | CO2018001624A2 (enExample) |
| EA (1) | EA201890530A1 (enExample) |
| HK (1) | HK1257056A1 (enExample) |
| IL (1) | IL257645A (enExample) |
| MX (1) | MX2018002166A (enExample) |
| PE (1) | PE20181292A1 (enExample) |
| PH (1) | PH12018500380A1 (enExample) |
| TW (1) | TW201718026A (enExample) |
| UY (1) | UY36862A (enExample) |
| WO (1) | WO2017031458A2 (enExample) |
| ZA (1) | ZA201801401B (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX383614B (es) | 2015-05-21 | 2025-03-14 | Harpoon Therapeutics Inc | Proteinas de union triespecificas y metodos de uso. |
| US10100106B2 (en) | 2016-05-20 | 2018-10-16 | Harpoon Therapeutics, Inc. | Single domain serum albumin binding protein |
| WO2018069289A1 (en) * | 2016-10-11 | 2018-04-19 | Medimmune Limited | Antibody-drug conjugates with immune-mediated therapy agents |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| SI3694529T1 (sl) | 2017-10-13 | 2024-10-30 | Harpoon Therapeutics, Inc. | Trispecifične beljakovine in načini uporabe |
| US11708410B2 (en) * | 2018-01-15 | 2023-07-25 | Nanjing Legend Biotech Co., Ltd. | Antibodies and variants thereof against TIGIT |
| BR112020023330A2 (pt) | 2018-05-14 | 2021-04-20 | Harpoon Therapeutics, Inc. | porção de ligação para ativação condicional de moléculas de imunoglobulina |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| US11673953B2 (en) | 2019-03-01 | 2023-06-13 | Allogene Therapeutics, Inc. | DLL3 targeting chimeric antigen receptors and binding agents |
| WO2020182517A1 (en) * | 2019-03-08 | 2020-09-17 | Oncolab Diagnostics Gmbh | Cancer diagnosis and prognosis |
| KR20220008866A (ko) | 2019-05-14 | 2022-01-21 | 하푼 테라퓨틱스, 인크. | EpCAM 결합 단백질 및 사용 방법 |
| CN114746115A (zh) * | 2019-06-07 | 2022-07-12 | 神话治疗股份有限公司 | 抗原结合蛋白构建体及其用途 |
| EP4056592A4 (en) * | 2019-11-08 | 2024-03-20 | Jiangsu Simcere Pharmaceutical Co., Ltd. | ANTIBODY AGAINST HUMAN PROGRAMMED CELL DEATH LIGAND 1 (PD-L1) AND USE THEREOF |
| EP3819312A1 (en) * | 2019-11-10 | 2021-05-12 | Amgen, Inc | Dosing regimen for anti-dll3 agents |
| CN115003325A (zh) * | 2019-12-20 | 2022-09-02 | 安托斯治疗股份有限公司 | 因子xi/xia抗体的药物制剂和剂量方案 |
| US20230227577A1 (en) * | 2020-05-05 | 2023-07-20 | Oncorus, Inc. | Anti-dll3 antibodies and methods of use |
| WO2022153194A1 (en) | 2021-01-13 | 2022-07-21 | Memorial Sloan Kettering Cancer Center | Antibody-pyrrolobenzodiazepine derivative conjugate |
| WO2022153195A1 (en) | 2021-01-13 | 2022-07-21 | Memorial Sloan Kettering Cancer Center | Anti-dll3 antibody-drug conjugate |
| KR20240006585A (ko) * | 2021-05-10 | 2024-01-15 | 암젠 인크 | Dll3 및 pd-1을 표적으로 하는 병용 요법을 위한 투여 요법 |
| CN116271079B (zh) * | 2021-07-30 | 2025-11-14 | 上海复旦张江生物医药股份有限公司 | 一种抗dll3抗体及其制备方法、其药物偶联物和应用 |
| EP4378955A4 (en) * | 2021-07-30 | 2025-10-22 | Shanghai Fudan Zhangjiang Bio Pharmaceutical Co Ltd | ANTI-DLL3 ANTIBODY AND PREPARATION METHOD THEREOF, DRUG CONJUGATE AND APPLICATION THEREOF |
| EP4396224A4 (en) * | 2021-09-02 | 2025-11-12 | Memorial Sloan Kettering Cancer Center | Anti-DLL3 Antibodies and Their Uses |
| CR20240135A (es) * | 2021-09-17 | 2024-05-17 | Wuxi Biologics Ireland Ltd | Moléculas de unión a d3 y usos de estas |
| CN114230666B (zh) * | 2021-12-20 | 2022-09-02 | 南京诺唯赞生物科技股份有限公司 | 一种t7 rna聚合酶的单克隆抗体及其制备方法 |
| EP4454662A4 (en) * | 2021-12-23 | 2025-04-23 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | ANTI-DLL3 ANTIBODY AND PHARMACEUTICAL USE THEREOF, AND ANTIBODY-DRUG CONJUGATE CONTAINING AN ANTI-DLL3 ANTIBODY |
| CN114369162B (zh) * | 2021-12-28 | 2023-05-30 | 合肥天港免疫药物有限公司 | 抗体及其应用 |
| KR20240153575A (ko) * | 2022-02-23 | 2024-10-23 | 암젠 인크 | Dll3을 표적화하는 암 치료 |
| CN114573698B (zh) * | 2022-03-16 | 2023-01-06 | 沈阳三生制药有限责任公司 | 一种FcRn抗原结合蛋白及其制备方法和应用 |
| CN121293357A (zh) | 2022-08-22 | 2026-01-09 | 雅博得乐医疗公司 | Dll3结合分子及其用途 |
| CN116253798B (zh) * | 2022-12-15 | 2023-10-27 | 华中农业大学 | 一株针对猪δ冠状病毒S1蛋白构象表位的中和性单克隆抗体 |
| CN116217715B (zh) | 2023-01-17 | 2023-08-15 | 山东农业大学 | 基于识别不同抗原决定簇的马铃薯y病毒单克隆抗体的组合及其应用 |
| WO2024179470A1 (zh) * | 2023-02-27 | 2024-09-06 | 苏州盛迪亚生物医药有限公司 | 抗dll3抗体、其抗体-药物偶联物及其医药用途 |
| WO2025190281A1 (en) * | 2024-03-11 | 2025-09-18 | Lepu Biopharma Co., Ltd. | Anti-dll3 antibodies and uses thereof |
| WO2025228330A1 (en) * | 2024-04-29 | 2025-11-06 | Fortvita Biologics (Singapore) Pte. Ltd. | Antibodies targeting dll3 and antibody-drug conjugates and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2014138474A (ru) * | 2012-02-24 | 2016-04-10 | СтемСентРкс, Инк. | Новые модуляторы и способы применения |
| SG10201801444WA (en) * | 2012-02-24 | 2018-04-27 | Abbvie Stemcentrx Llc | Anti sez6 antibodies and methods of use |
| ES2738310T3 (es) * | 2012-10-12 | 2020-01-21 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas |
| MX2015010682A (es) * | 2013-02-22 | 2016-05-31 | Stemcentrx Inc | Nuevos conjugados de anticuerpos y usos de los mismos. |
| US20160106861A1 (en) * | 2013-04-26 | 2016-04-21 | Spirogen Sarl | Axl antibody-drug conjugate and its use for the treatment of cancer |
| RU2016111137A (ru) * | 2013-08-28 | 2017-10-03 | ЭББВИ СТЕМСЕНТРКС ЭлЭлСи | Сконструированные конъюгаты против dll3 и способы применения |
| PE20160674A1 (es) * | 2013-08-28 | 2016-07-21 | Stemcentrx Inc | Metodos de conjugacion de anticuerpos especificos de sitio y composiciones |
| EP3054983B1 (en) * | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| WO2015052533A1 (en) * | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| EP3054985B1 (en) * | 2013-10-11 | 2018-12-26 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| EP3054986B1 (en) * | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
-
2016
- 2016-08-19 MX MX2018002166A patent/MX2018002166A/es unknown
- 2016-08-19 EP EP16837930.3A patent/EP3337517A4/en not_active Withdrawn
- 2016-08-19 UY UY0001036862A patent/UY36862A/es not_active Application Discontinuation
- 2016-08-19 EA EA201890530A patent/EA201890530A1/ru unknown
- 2016-08-19 AU AU2016308365A patent/AU2016308365A1/en not_active Abandoned
- 2016-08-19 KR KR1020187007525A patent/KR20180041717A/ko not_active Withdrawn
- 2016-08-19 BR BR112018003269A patent/BR112018003269A2/pt not_active Application Discontinuation
- 2016-08-19 US US15/753,509 patent/US20180243435A1/en not_active Abandoned
- 2016-08-19 HK HK18116192.2A patent/HK1257056A1/zh unknown
- 2016-08-19 CN CN201680061029.8A patent/CN108136015A/zh active Pending
- 2016-08-19 JP JP2018509504A patent/JP2018529656A/ja not_active Ceased
- 2016-08-19 PE PE2018000271A patent/PE20181292A1/es unknown
- 2016-08-19 CA CA2996165A patent/CA2996165A1/en not_active Abandoned
- 2016-08-19 TW TW105126609A patent/TW201718026A/zh unknown
- 2016-08-19 WO PCT/US2016/047870 patent/WO2017031458A2/en not_active Ceased
-
2018
- 2018-02-20 CO CONC2018/0001624A patent/CO2018001624A2/es unknown
- 2018-02-20 PH PH12018500380A patent/PH12018500380A1/en unknown
- 2018-02-20 IL IL257645A patent/IL257645A/en unknown
- 2018-02-20 CL CL2018000458A patent/CL2018000458A1/es unknown
- 2018-02-28 ZA ZA2018/01401A patent/ZA201801401B/en unknown
- 2018-12-21 CL CL2018003758A patent/CL2018003758A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL295418B1 (en) | Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus | |
| JP2015078230A5 (enExample) | ||
| JP2017537066A5 (enExample) | ||
| JP2014177455A5 (enExample) | ||
| JP2013518107A5 (enExample) | ||
| JP2015516989A5 (enExample) | ||
| JP2017509667A5 (enExample) | ||
| WO2018104909A3 (en) | Dna methylation profiling for t-cell immunotherapy | |
| MX2014011510A (es) | Composicion farmaceutica que comprende olmesartan medoxomilo y rosuvastatina o su sal. | |
| MX2009012598A (es) | Formas de dosis que comprenden vx-950 y su regimen de dosificacion. | |
| ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| ZA202409847B (en) | Gastro-resistant controlled release oral dosage forms | |
| JP2015507020A5 (enExample) | ||
| JP2017516827A5 (enExample) | ||
| JP2017531686A5 (enExample) | ||
| JP2019517507A5 (enExample) | ||
| CL2016002318A1 (es) | Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits. | |
| JP2017527551A5 (enExample) | ||
| JP2017529355A5 (enExample) | ||
| JP2015044878A5 (enExample) | ||
| AR117087A1 (es) | Composición farmacéutica de fruquintinib y uso de la misma | |
| CN110049765A (zh) | 一种组合、其应用及治疗方法 | |
| JP2019515942A5 (enExample) | ||
| JP2017517574A5 (enExample) | ||
| EA201791848A1 (ru) | Композиция фосфорамидата нуклеотида |